Position in DFTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,763,200
+$3,763,200 QoQ
Shares Held
80,000
Ownership
0.060%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
#109
of 355 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in DFTX
reported options exposure · as of Jun 30, 2026CallValue
$470,400
CallShares
10,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Shay Capital LLC holds $28,794,197 across 40 Biotechnology names. DFTX ranks #1 (13.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
This page
|
80,000 | $3,763,200 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
44,000 | $3,586,440 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
12,500 | $2,341,000 | |
| 4 | MANE |
Veradermics, Inc
|
19,000 | $2,335,860 | |
| 5 | BCAX |
Bicara Therapeutics Inc.
|
68,000 | $2,018,920 | |
| 6 | QURE |
uniQure N.V.
|
37,419 | $1,723,519 | |
| 7 | AVLN |
Avalyn Pharma Inc.
|
40,000 | $1,316,800 | |
| 8 | PGEN |
Precigen, Inc.
|
190,000 | $1,083,000 |
All Filings in DFTX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $470,400 | 10,000 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $3,763,200 | 80,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $189,000 | 10,000 | Call | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||